Exhibit 99.1 ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Topline Results from Investigator-Initiated Clinic ...